Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 8/20 | 0.63 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.63 |
| ▸ | PIM1 | P11309 | 2/20 | 0.63 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29428185 | 1.00 | PARP1 (0.63) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL1257333 | 0.87 | PARP1 (0.63) | PARP1CHEK1PIM1ALDH1A1MMP12 | |
| SCHEMBL29235186 | 0.84 | IP6K1 (0.47) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL5565888 | 0.83 | PARP1 (0.55) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL17740845 | 0.81 | PARP1 (0.56) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL30101173 | 0.81 | PARP1 (0.52) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL4497910 | 0.80 | PARP1 (0.51) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL6824901 | 0.80 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 | |
| SCHEMBL6869415 | 0.80 | ACVR1 (0.63) | PARP1CHEK1PIM1ALDH1A1MMP12 | |
| SCHEMBL27246028 | 0.79 | IP6K1 (0.48) | PARP1CHEK1PIM1RPS6KA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466942-A | Chiral secondary phosphine oxide compound, chiral quinazolinone/pyrimidinone ring derivative based on chiral secondary phosphine oxide compound and application of chiral quinazolinone/pyrimidinone ring derivative | 中山大学 | 2024-01-30 | — | — | CN | disclosed |
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-05-05 | — | — | US | disclosed |
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-21 | — | — | US | disclosed |
| EP-3762379-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
| WO-2019170543-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-09-12 | — | — | WO | disclosed |
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966159-A2 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071963-A2 | QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-6903107-B1 | Serine protease inhibitor | AKZO NOBEL N.V. (NL) | 2005-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306096-A1 | Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer Agents | BRAF, RAF1, NRAS | PARP1 1048/4885CHEK1 310/4885PIM1 545/4885 |
| US-20210017174-A1 | IDENTIFICATION AND USE OF ERK5 INHIBITOR | MAPK15, MAPKAPK5, MAP3K5 | PARP1 2057/4885CHEK1 198/4885PIM1 768/4885 |
| US-20220135598-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, ENPP2 | PARP1 982/4885CHEK1 4194/4885PIM1 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.